These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 15848674

  • 21. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
    Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR.
    J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids.
    Otero A, Varo E, de Urbina JO, Martín-Vivaldi R, Cuervas-Mons V, González-Pinto I, Rimola A, Bernardos A, Otero S, Maldonado J, Herrero JI, Barrao E, Domínguez-Granados R.
    Liver Transpl; 2009 Nov; 15(11):1542-52. PubMed ID: 19877219
    [Abstract] [Full Text] [Related]

  • 24. Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation.
    Orr DW, Portmann BC, Knisely AS, Stoll S, Rela M, Muiesan P, Bowles MJ, Heaton ND, O'Grady JG, Heneghan MA.
    Transplant Proc; 2005 Dec; 37(10):4373-9. PubMed ID: 16387124
    [Abstract] [Full Text] [Related]

  • 25. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil.
    Washburn K, Speeg KV, Esterl R, Cigarroa F, Pollack M, Tourtellot C, Maxwell P, Halff G.
    Transplantation; 2001 Nov 27; 72(10):1675-9. PubMed ID: 11726831
    [Abstract] [Full Text] [Related]

  • 26. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.
    Testillano M, Fernandez JR, Suarez MJ, Gastaca M, Bustamante J, Pijoan JI, Montejo M, Valdivieso A, Ruiz P, Gonzalez J, Ortiz de Urbina J.
    Transplant Proc; 2009 Apr 27; 41(3):1041-3. PubMed ID: 19376421
    [Abstract] [Full Text] [Related]

  • 27. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation.
    Takada Y, Kaido T, Asonuma K, Sakurai H, Kubo S, Kiuchi T, Inomata Y, Isaji S, Tsumura H, Teramukai S, Matsubara Y, Sakabayashi S, Uemoto S.
    Liver Transpl; 2013 Aug 27; 19(8):896-906. PubMed ID: 23696054
    [Abstract] [Full Text] [Related]

  • 28. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation.
    Sarwal MM, Yorgin PD, Alexander S, Millan MT, Belson A, Belanger N, Granucci L, Major C, Costaglio C, Sanchez J, Orlandi P, Salvatierra O.
    Transplantation; 2001 Jul 15; 72(1):13-21. PubMed ID: 11468528
    [Abstract] [Full Text] [Related]

  • 29. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.
    Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit C, Margreiter R, Pallardo JM, Hoeckerstedt K, Pageaux GP.
    Liver Transpl; 2005 Jan 15; 11(1):61-7. PubMed ID: 15690537
    [Abstract] [Full Text] [Related]

  • 30. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
    Stravitz RT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Heuman DM, Ashworth A, Mills AS, Contos M, Cotterell AH, Maluf D, Posner MP, Fisher RA.
    Liver Transpl; 2004 Jul 15; 10(7):850-8. PubMed ID: 15237368
    [Abstract] [Full Text] [Related]

  • 31. Pediatric liver transplantation with daclizumab induction.
    Heffron TG, Pillen T, Smallwood GA, Welch D, Oakley B, Romero R.
    Transplantation; 2003 Jun 27; 75(12):2040-3. PubMed ID: 12829908
    [Abstract] [Full Text] [Related]

  • 32. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial.
    Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, Peltekian KM, Lilly LB, Scudamore CH, Bain VG, Wall WJ, Roy A, Balshaw RF, Barkun JS.
    Liver Transpl; 2005 Sep 27; 11(9):1064-72. PubMed ID: 16123958
    [Abstract] [Full Text] [Related]

  • 33. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy.
    Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE.
    Transplantation; 2003 Apr 27; 75(8):1396-9. PubMed ID: 12717237
    [Abstract] [Full Text] [Related]

  • 34. A novel immunosuppressive strategy combined with preemptive antiviral therapy improves the eighteen-month mortality in HCV recipients transplanted with aged livers.
    Urbani L, Mazzoni A, Colombatto P, Bindi L, Biancofiore G, Tascini C, Menichetti F, Brunetto MR, Scatena F, Filipponi F.
    Transplantation; 2008 Dec 27; 86(12):1666-71. PubMed ID: 19104402
    [Abstract] [Full Text] [Related]

  • 35. Daclizumab to prevent rejection after cardiac transplantation.
    Hershberger RE, Starling RC, Eisen HJ, Bergh CH, Kormos RL, Love RB, Van Bakel A, Gordon RD, Popat R, Cockey L, Mamelok RD.
    N Engl J Med; 2005 Jun 30; 352(26):2705-13. PubMed ID: 15987919
    [Abstract] [Full Text] [Related]

  • 36. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
    Montini G, Murer L, Ghio L, Pietrobon B, Ginevri F, Ferraresso M, Cardillo M, Scalamogna M, Perfumo F, Edefonti A, Zanon GF, Zacchello G.
    Transpl Int; 2005 Jan 30; 18(1):36-42. PubMed ID: 15612981
    [Abstract] [Full Text] [Related]

  • 37. Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation.
    Moreno Planas JM, Rubio Gonzalez E, Boullosa Graña E, Garrido Botella A, Barrios Peinado C, Lucena Poza JL, Jiménez Garrido M, Sanchez Turrion V, Cuervas-Mons Martinez V.
    Transplant Proc; 2005 Jun 30; 37(5):2207-8. PubMed ID: 15964380
    [Abstract] [Full Text] [Related]

  • 38. Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients.
    Calmus Y, Kamar N, Gugenheim J, Duvoux C, Ducerf C, Wolf P, Samuel D, Vanlemmens C, Neau-Cransac M, Salamé E, Chazouillères O, Declerck N, Pageaux GP, Dubel L, Rostaing L.
    Transplantation; 2010 Jun 27; 89(12):1504-10. PubMed ID: 20495510
    [Abstract] [Full Text] [Related]

  • 39. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
    Emre S, Gondolesi G, Polat K, Ben-Haim M, Artis T, Fishbein TM, Sheiner PA, Kim-Schluger L, Schwartz ME, Miller CM.
    Liver Transpl; 2001 Mar 27; 7(3):220-5. PubMed ID: 11244163
    [Abstract] [Full Text] [Related]

  • 40. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy.
    Toniutto P, Fabris C, Fumo E, Apollonio L, Caldato M, Avellini C, Minisini R, Pirisi M.
    J Gastroenterol Hepatol; 2005 Apr 27; 20(4):577-82. PubMed ID: 15836706
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.